Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(1):108–113. doi: 10.1038/sj.bjc.6690658

Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer

Y Harima 1, S Shirahama 2, K Harima 1, S Aoki 2, T Ohnishi 3, Y Tanaka 1
PMCID: PMC2374353  PMID: 10487620

Abstract

Chromosome 17 alterations are found in more cancers than those of any other chromosome, and frequently involve the p53 gene on 17p13. The aim of this study was to identify the correlations between the presence of loss of heterozygosity (LOH) and microsatellite instability (MI) on chromosome 17p13 in patients with cervical cancer and the patients’ response to radiotherapy. A total of 50 patients were treated with definitive radiotherapy. We performed biopsies and took specimens from the tumour and venous blood of all patients. Tumour and normal DNAs were analysed by polymerase chain reaction for genetic losses and instability at three polymorphic microsatellite loci mapped to 17p13. Nineteen of the 50 tumours (38%) displayed a genetic alteration (GA) on 17p13, 16 (32%) were found to have LOH, and three (6%) showed MI. The sizes of the tumours of the GA-positive patients were significantly greater than those of the GA-negative patients (P = 0.009). The mean tumour diameter of all patients was 6 ± 2.4 cm. We divided the patients into those with tumours smaller than 6 cm in diameter (n = 26) and those with tumours equal to or greater than 6 cm in diameter (n = 24). The former group survived significantly longer compared to the latter group (P = 0.0002). Among the patients with < 6 cm tumours, all six GA-positive patients are alive with no evidence of disease (NED), whereas of the 20 GA-negative patients, 18 have NED and two are alive with disease (AWD) or suffered cancer-caused death (CD). Thus, there was no correlation between GA and radiotherapy response in the tumours smaller than 6 cm. However, among the patients with ≥ 6 cm tumours, two of the GA-positive patients have NED and 11 are AWD/CD, whereas seven of the GA-negative patients have NED and four are AWD/CD. Among the patients with ≥ 6 cm tumours, the response to radiotherapy of the GA-positive patients were significantly poorer than those of the GA-negative patients (P = 0.02). In addition, the GA-negative patients survived significantly longer compared to the GA-positive patients (P = 0.026). The results of this study suggest that GA increases with tumour growth. Improved success in the management of bulky cervical cancer requires a better understanding of its biological behaviour. © 1999 Cancer Research Campaign

Keywords: loss of heterozygosity, microsatellite instability, radiotherapy, cervical carcinoma

Full Text

The Full Text of this article is available as a PDF (128.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aas T., Børresen A. L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J. E., Akslen L. A., Lønning P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996 Jul;2(7):811–814. doi: 10.1038/nm0796-811. [DOI] [PubMed] [Google Scholar]
  2. Ahnen D. J., Feigl P., Quan G., Fenoglio-Preiser C., Lovato L. C., Bunn P. A., Jr, Stemmerman G., Wells J. D., Macdonald J. S., Meyskens F. L., Jr Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998 Mar 15;58(6):1149–1158. [PubMed] [Google Scholar]
  3. Atkin N. B., Baker M. C., Fox M. F. Chromosome changes in 43 carcinomas of the cervix uteri. Cancer Genet Cytogenet. 1990 Feb;44(2):229–241. doi: 10.1016/0165-4608(90)90052-c. [DOI] [PubMed] [Google Scholar]
  4. Bronner C. E., Baker S. M., Morrison P. T., Warren G., Smith L. G., Lescoe M. K., Kane M., Earabino C., Lipford J., Lindblom A. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 1994 Mar 17;368(6468):258–261. doi: 10.1038/368258a0. [DOI] [PubMed] [Google Scholar]
  5. Burger R. A., Monk B. J., Kurosaki T., Anton-Culver H., Vasilev S. A., Berman M. L., Wilczynski S. P. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst. 1996 Oct 2;88(19):1361–1368. doi: 10.1093/jnci/88.19.1361. [DOI] [PubMed] [Google Scholar]
  6. Butz K., Shahabeddin L., Geisen C., Spitkovsky D., Ullmann A., Hoppe-Seyler F. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene. 1995 Mar 2;10(5):927–936. [PubMed] [Google Scholar]
  7. Chang F., Syrjänen S., Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol. 1995 Apr;13(4):1009–1022. doi: 10.1200/JCO.1995.13.4.1009. [DOI] [PubMed] [Google Scholar]
  8. Chen T. M., Chen C. A., Hsieh C. Y., Chang D. Y., Chen Y. H., Defendi V. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells. Oncogene. 1993 Jun;8(6):1511–1518. [PubMed] [Google Scholar]
  9. Dib C., Fauré S., Fizames C., Samson D., Drouot N., Vignal A., Millasseau P., Marc S., Hazan J., Seboun E. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996 Mar 14;380(6570):152–154. doi: 10.1038/380152a0. [DOI] [PubMed] [Google Scholar]
  10. Fishel R., Lescoe M. K., Rao M. R., Copeland N. G., Jenkins N. A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993 Dec 3;75(5):1027–1038. doi: 10.1016/0092-8674(93)90546-3. [DOI] [PubMed] [Google Scholar]
  11. GEHAN E. A. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika. 1965 Jun;52:203–223. [PubMed] [Google Scholar]
  12. Higgins G. D., Davy M., Roder D., Uzelin D. M., Phillips G. E., Burrell C. J. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet. 1991 Oct 12;338(8772):910–913. doi: 10.1016/0140-6736(91)91773-n. [DOI] [PubMed] [Google Scholar]
  13. Iwasawa A., Nieminen P., Lehtinen M., Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer. 1996 Jun 1;77(11):2275–2279. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2275::AID-CNCR14>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  14. Jones M. H., Koi S., Fujimoto I., Hasumi K., Kato K., Nakamura Y. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer. 1994 Feb;9(2):119–123. doi: 10.1002/gcc.2870090207. [DOI] [PubMed] [Google Scholar]
  15. Jones M. H., Nakamura Y. Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms. Oncogene. 1992 Aug;7(8):1631–1634. [PubMed] [Google Scholar]
  16. King L. A., Tase T., Twiggs L. B., Okagaki T., Savage J. E., Adcock L. L., Prem K. A., Carson L. F. Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix. Cancer. 1989 Mar 1;63(5):897–900. doi: 10.1002/1097-0142(19890301)63:5<897::aid-cncr2820630517>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  17. Kohno T., Takayama H., Hamaguchi M., Takano H., Yamaguchi N., Tsuda H., Hirohashi S., Vissing H., Shimizu M., Oshimura M. Deletion mapping of chromosome 3p in human uterine cervical cancer. Oncogene. 1993 Jul;8(7):1825–1832. [PubMed] [Google Scholar]
  18. Kristensen G. B., Karlsen F., Jenkins A., Kaern J., Abeler V. M., Tropé C. G. Human papilloma virus has no prognostic significance in cervical carcinoma. Eur J Cancer. 1996 Jul;32A(8):1349–1353. doi: 10.1016/0959-8049(96)00089-5. [DOI] [PubMed] [Google Scholar]
  19. Leach F. S., Nicolaides N. C., Papadopoulos N., Liu B., Jen J., Parsons R., Peltomäki P., Sistonen P., Aaltonen L. A., Nyström-Lahti M. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993 Dec 17;75(6):1215–1225. doi: 10.1016/0092-8674(93)90330-s. [DOI] [PubMed] [Google Scholar]
  20. Li X., Lee N. K., Ye Y. W., Waber P. G., Schweitzer C., Cheng Q. C., Nisen P. D. Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst. 1994 Oct 19;86(20):1524–1529. doi: 10.1093/jnci/86.20.1524. [DOI] [PubMed] [Google Scholar]
  21. Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E., Housman D. E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994 Nov 4;266(5186):807–810. doi: 10.1126/science.7973635. [DOI] [PubMed] [Google Scholar]
  22. Lynch H. T., Smyrk T. C., Watson P., Lanspa S. J., Lynch J. F., Lynch P. M., Cavalieri R. J., Boland C. R. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 1993 May;104(5):1535–1549. doi: 10.1016/0016-5085(93)90368-m. [DOI] [PubMed] [Google Scholar]
  23. Marshall C. J. Tumor suppressor genes. Cell. 1991 Jan 25;64(2):313–326. doi: 10.1016/0092-8674(91)90641-b. [DOI] [PubMed] [Google Scholar]
  24. Matsumoto K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Jpn J Cancer Res. 1997 Apr;88(4):369–375. doi: 10.1111/j.1349-7006.1997.tb00391.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mitra A. B., Murty V. V., Li R. G., Pratap M., Luthra U. K., Chaganti R. S. Allelotype analysis of cervical carcinoma. Cancer Res. 1994 Aug 15;54(16):4481–4487. [PubMed] [Google Scholar]
  26. Mullokandov M. R., Kholodilov N. G., Atkin N. B., Burk R. D., Johnson A. B., Klinger H. P. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res. 1996 Jan 1;56(1):197–205. [PubMed] [Google Scholar]
  27. Papadopoulos N., Nicolaides N. C., Wei Y. F., Ruben S. M., Carter K. C., Rosen C. A., Haseltine W. A., Fleischmann R. D., Fraser C. M., Adams M. D. Mutation of a mutL homolog in hereditary colon cancer. Science. 1994 Mar 18;263(5153):1625–1629. doi: 10.1126/science.8128251. [DOI] [PubMed] [Google Scholar]
  28. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990 Dec 21;63(6):1129–1136. doi: 10.1016/0092-8674(90)90409-8. [DOI] [PubMed] [Google Scholar]
  29. Schiffman M. H. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 1992 Mar 18;84(6):394–398. doi: 10.1093/jnci/84.6.394. [DOI] [PubMed] [Google Scholar]
  30. Srivatsan E. S., Misra B. C., Venugopalan M., Wilczynski S. P. Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. Am J Hum Genet. 1991 Oct;49(4):868–877. [PMC free article] [PubMed] [Google Scholar]
  31. Virostek L. J., Kim R. Y., Spencer S. A., Meredith R. F., Jennelle R. L., Soong S. J., Salter M. M. Postsurgical recurrent carcinoma of the cervix: reassessment and results of radiation therapy options. Radiology. 1996 Nov;201(2):559–563. doi: 10.1148/radiology.201.2.8888258. [DOI] [PubMed] [Google Scholar]
  32. Yoshikawa H., Kawana T., Kitagawa K., Mizuno M., Yoshikura H., Iwamoto A. Amplification and typing of multiple cervical cancer-associated human papillomavirus DNAs using a single pair of primers. Int J Cancer. 1990 May 15;45(5):990–992. doi: 10.1002/ijc.2910450537. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES